Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics


Vanda Pharmaceuticals Inc. (VNDA): $9.92

0.03 (+0.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VNDA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VNDA POWR Grades


  • VNDA scores best on the Value dimension, with a Value rank ahead of 99.7% of US stocks.
  • The strongest trend for VNDA is in Growth, which has been heading down over the past 179 days.
  • VNDA ranks lowest in Growth; there it ranks in the 6th percentile.

VNDA Stock Summary

  • For VNDA, its debt to operating expenses ratio is greater than that reported by merely 9.8% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.17 for Vanda Pharmaceuticals Inc; that's greater than it is for only 11.67% of US stocks.
  • With a year-over-year growth in debt of -12.54%, Vanda Pharmaceuticals Inc's debt growth rate surpasses 26.93% of about US stocks.
  • Stocks that are quantitatively similar to VNDA, based on their financial statements, market capitalization, and price volatility, are NATI, THRM, WB, CLPT, and MDRX.
  • VNDA's SEC filings can be seen here. And to visit Vanda Pharmaceuticals Inc's official web site, go to www.vandapharma.com.

VNDA Valuation Summary

  • In comparison to the median Healthcare stock, VNDA's price/earnings ratio is 21.37% lower, now standing at 28.7.
  • VNDA's price/sales ratio has moved NA NA over the prior 187 months.
  • Over the past 187 months, VNDA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VNDA.

Stock Date P/S P/B P/E EV/EBIT
VNDA 2021-08-31 3.6 1.9 28.7 20.9
VNDA 2021-08-30 3.6 2.0 29.0 21.1
VNDA 2021-08-27 3.7 2.0 29.6 21.6
VNDA 2021-08-26 3.6 1.9 28.5 20.7
VNDA 2021-08-25 3.6 1.9 28.7 20.9
VNDA 2021-08-24 3.5 1.9 27.6 20.1

VNDA Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at 377.72%.
  • Its year over year price growth rate is now at 55.92%.
  • The 2 year price growth rate now stands at -19.5%.
VNDA's revenue has moved up $147,645,000 over the prior 70 months.

The table below shows VNDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 268.682 64.214 33.152
2021-09-30 268.316 56.909 34.264
2021-06-30 258.529 56.886 32.44
2021-03-31 252.837 61.875 31.501
2020-12-31 248.168 51.775 23.337
2020-09-30 241.445 42.264 19.363

VNDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNDA has a Quality Grade of B, ranking ahead of 90.12% of graded US stocks.
  • VNDA's asset turnover comes in at 0.483 -- ranking 88th of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and AMRN are the stocks whose asset turnover ratios are most correlated with VNDA.

The table below shows VNDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.483 0.904 0.107
2021-06-30 0.479 0.904 0.105
2021-03-31 0.482 0.904 0.107
2020-12-31 0.486 0.906 0.086
2020-09-30 0.484 0.904 0.073
2020-06-30 0.493 0.900 0.085

VNDA Price Target

For more insight on analysts targets of VNDA, see our VNDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1 (Strong Buy)

VNDA Stock Price Chart Interactive Chart >

Price chart for VNDA

VNDA Price/Volume Stats

Current price $9.92 52-week high $21.86
Prev. close $9.89 52-week low $9.24
Day low $9.63 Volume 468,700
Day high $10.13 Avg. volume 562,144
50-day MA $10.88 Dividend yield N/A
200-day MA $14.74 Market Cap 560.38M

Vanda Pharmaceuticals Inc. (VNDA) Company Bio


Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The company was founded in 2002 and is based in Washington, the District of Columbia.


VNDA Latest News Stream


Event/Time News Detail
Loading, please wait...

VNDA Latest Social Stream


Loading social stream, please wait...

View Full VNDA Social Stream

Latest VNDA News From Around the Web

Below are the latest news stories about Vanda Pharmaceuticals Inc that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2021.

Yahoo | February 23, 2022

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes.

Yahoo | February 17, 2022

Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More

Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.

Yahoo | February 9, 2022

Why Are Vanda Pharma Shares Plunging Today?

Vanda Pharmaceuticals Inc (NASDAQ: VNDA ) shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis. Gastroparesis is a condition that reduces the ability of the stomach to empty its contents. It does not involve a blockage (obstruction). The study did not meet its prespecified primary endpoint , the difference between drug and placebo on the severity of nausea from baseline at Full story available on Benzinga.com

Benzinga | February 4, 2022

Vanda falls 21% as tradipitant fails in phase 3 study for gastroparesis

Vanda Pharmaceuticals'' (VNDA) medicine tradipitant failed to beat placebo in a phase 3 trial to treat symptoms of gastroparesis.The study, dubbed VP-VLY-686-3303, did not meet its main

Seeking Alpha | February 4, 2022

Read More 'VNDA' Stories Here

VNDA Price Returns

1-mo -8.49%
3-mo -26.03%
6-mo -42.43%
1-year -46.35%
3-year -37.22%
5-year -30.14%
YTD -36.78%
2021 19.41%
2020 -19.93%
2019 -37.20%
2018 71.91%
2017 -4.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5665 seconds.